Lamellar Biomedical’s LMS-611, an inhaled Lamellasome, an artificial lamellar body, for the treatment of patients with cystic fibrosis has received orphan drug designation from the European Commission. CF patients’ lungs may be missing lamellar bodies that can serve as lubricants and surfactants. The company says that it has data showing that LMS-611 has “significant potential as a mucus-altering treatment with the ability to fight and prevent infection.”
“The designation of LMS-611 as an orphan drug by the European Medicines Agency underscores the importance of developing effective treatments for patients with cystic fibrosis,” said Lamellar CBO Iain McDougall. “To date we have been extremely encouraged by LMS-611’s preclinical results, and we continue to believe we are developing a therapy which will prove to be both safe and effective with the potential to offer a brand new way of treating the disease when we enter clinical trials early next year.”
Read the Lamellar press release.
